Rep. Thomas H. Kean, Jr. Buys Shares of Abbott Laboratories (NYSE:ABT)

Key Points

• Representative Thomas H. Kean, Jr. purchased shares of Abbott Laboratories (NYSE:ABT) valued between $1,001 and $15,000 on July 21st, according to a filing.
• Abbott Laboratories recently reported $1.26 earnings per share for the last quarter, matching analysts' expectations, with a quarterly revenue rise of 7.4% year-over-year.
• The company also announced a quarterly dividend of $0.59, translating to an annualized yield of 1.8%, with a dividend payout ratio of 29.57%.

Representative Thomas H. Kean, Jr. (R-New Jersey) recently bought shares of Abbott Laboratories NYSE: ABT. In a filing disclosed on August 20th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on July 21st. The trade occurred in the Representative's "KEAN FAMILY PARTNERSHIP" account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Stryker NYSE: SYK on 7/31/2025.
• Sold $15,001 - $50,000 in shares of Johnson & Johnson NYSE: JNJ on 7/31/2025.
• Purchased $15,001 - $50,000 in shares of Check Point Software Technologies NASDAQ: CHKP on 7/29/2025.
• Sold $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 7/29/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 6/30/2025.
• Sold $15,001 - $50,000 in shares of Stryker NYSE: SYK on 6/26/2025.
• Sold $1,001 - $15,000 in shares of WESCO International NYSE: WCC on 6/23/2025.
• Purchased $1,001 - $15,000 in shares of Danaher NYSE: DHR on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of AON NYSE: AON on 5/27/2025.

Abbott Laboratories Trading Down 0.4%

Shares of Abbott Laboratories stock opened at $131.9580 on Friday. The stock has a market capitalization of $229.67 billion, a P/E ratio of 16.54, a P/E/G ratio of 2.51 and a beta of 0.70. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The stock's 50-day simple moving average is $131.14 and its 200 day simple moving average is $131.27.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same quarter last year, the business earned $1.14 earnings per share. The company's quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were issued a $0.59 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Royal Bank Of Canada lifted their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a research note on Tuesday, July 15th. BTIG Research reduced their price target on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research report on Friday, July 18th. William Blair raised Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Raymond James Financial cut their target price on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research note on Friday, July 18th. Finally, Wells Fargo & Company decreased their price target on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a research report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $144.47.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors have recently added to or reduced their stakes in ABT. Brighton Jones LLC lifted its position in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Bank Pictet & Cie Europe AG raised its position in shares of Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after buying an additional 2,774 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Abbott Laboratories by 20.9% during the 4th quarter. First Trust Advisors LP now owns 719,317 shares of the healthcare product maker's stock worth $81,362,000 after acquiring an additional 124,259 shares during the last quarter. Van Lanschot Kempen Investment Management N.V. grew its position in Abbott Laboratories by 39.8% in the fourth quarter. Van Lanschot Kempen Investment Management N.V. now owns 66,059 shares of the healthcare product maker's stock worth $7,472,000 after acquiring an additional 18,802 shares in the last quarter. Finally, Alta Advisers Ltd grew its position in Abbott Laboratories by 21.7% in the fourth quarter. Alta Advisers Ltd now owns 5,720 shares of the healthcare product maker's stock worth $647,000 after acquiring an additional 1,020 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company's stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.46% of the stock is owned by insiders.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.